A one-stop-shop CRO bringing together innovative platforms, strategic solutions and specialized expertise to drive drug development and advance diverse fields of research.
Policies, Terms & Conditions
At Firalis Molecular Precision, we specialize in providing cutting-edge bioinformatics services that support a wide range of omics analyses.
As a CRO, we understand the complexity and significance of data in scientific research, and our goal is to empower our clients with the tools and expertise needed to unlock actionable insights from their data.
Today, we address some of the most frequently asked questions about our bioinformatics services. Whether you’re looking to store, transfer, or analyze complex datasets, we offer comprehensive solutions for proteomics, genomics, transcriptomics, and more.
How are the datasets stored at Firalis Molecular Precision?
We store datasets internally on our servers.
Upon generation, files are initially stored in a high-performance storage system, allowing for immediate analysis.
Subsequently, they are transferred to a cost-effective, long-term storage system. This transition typically occurs after a period of three months, as agreed upon between Firalis Molecular Precision and the client.
Following this period, we will contact the client to either arrange for data deletion or extend the storage duration.
How will the data/which type of data will be sent to me?
To initiate the project, we will collaborate with you to draft a Data Transfer Agreement (DTA) that outlines specific details such as data types, estimated data volume, and the preferred transfer method.
At Firalis Molecular Precision, we are committed to delivering data in the desired format, including CDISC standards.
For data transfer, we offer flexible options: you can either access the data via an SFTP link or connect to our Azure storage.
Alternatively, if you have a proprietary platform, we can seamlessly integrate with your system.
What types of omics data can your team process and analyze?
Our team is equipped to process all omics data generated at Firalis Molecular Precision, including proteomics, genomics, epigenomics, and both bulk and single-cell transcriptomics.
What advanced technologies and analyses do you specialize in?
We are at the forefront of cutting-edge technologies, including spatial transcriptomics data analysis.
Our services encompass primary and secondary analyses, such as data quality control (QC), preprocessing (demultiplexing, reads trimming, alignment on reference genome), and more advanced bioinformatics analyses like differential expression, pathway enrichment, and other statistical analyses.
Can you help analyze data that I’ve already generated?
Supporting our clients in analyzing their data is at the heart of what we do.
We offer a range of services, from personalized training and consulting to full-service data analysis, ensuring that you get the most out of your data.
Which type of tertiary analysis can you provide?
Every project is unique, tailored to your specific biological question.
Our bioinformatics experts collaborate closely with you from the outset to fully understand your technical and scientific needs. This allows us to develop a customized analysis strategy that directly addresses your goals.
For example, single-cell RNA-seq analysis is highly versatile and not confined to a one-size-fits-all pipeline.
The decision to use this technique can stem from a myriad of biological questions. Here are a few examples:
- Cellular Composition Changes: If you’re interested in how cell types within a sample (like blood) change before and after a treatment, we would focus on cell type annotation. This involves searching for well-annotated reference datasets and cross-referencing them with published literature. A crucial step here is normalizing and integrating data from multiple samples or batches to enable meaningful comparisons.
- Cell Line Homogeneity: When validating a new cell line, the analysis shifts towards identifying the underlying factors contributing to the main patterns observed in the data. Dimensionality reduction techniques like PCA and UMAP can help uncover hidden subpopulations with distinct transcriptomes. Additionally, cell cycle analysis can provide valuable insights into the homogeneity of the cell line.
- Impact of Anti-Cancer Drugs on Cellular Differentiation: Many cancers, particularly leukemias, are characterized by a block in the differentiation of progenitor cells into mature cells. One way to assess the efficacy of an anti-cancer drug is to examine its effect on restoring normal differentiation. Single-cell analysis can identify the various stages of normal differentiation (through pseudotime analysis) and determine whether the drug is able to promote this process.
Naturally, this strategy can be applied to all omics technologies.
WGS/WES – What level of sequencing coverage is required for detecting polymorphisms?
For germline polymorphisms, a sequencing depth of 30X is usually sufficient to identify the most relevant genetic information.
However, for somatic mutation detection, particularly in cancer research, a much deeper sequencing depth of 1000X is necessary. This higher coverage is essential to accurately identify subtle genetic alterations that may play a role in cancer development and progression.
RNA-seq – How many sequencing reads are needed for differential expression analysis or transcriptome reconstruction?
If your primary focus is on mRNA transcripts, a sequencing depth of 15 to 20 million reads is sufficient to capture most of the relevant information.
However, for analyzing other types of transcripts, such as long non-coding RNAs (lncRNAs), a significantly higher sequencing depth of 200 million reads is recommended. This increased depth is essential for detecting lncRNAs, which are often expressed at low levels, and for performing accurate differential expression analysis.
Additionally, a sequencing depth of 200 million reads is necessary for de novo transcriptome assembly, which involves reconstructing the entire transcriptome from scratch, allowing for the discovery of novel transcripts.
Have More Questions?
If you have additional questions or need further information, our experts are here to help! Don’t hesitate to reach out—we’re committed to supporting your research and drug development journey.
To learn more about our comprehensive bioinformatics services, visit our dedicated webpage.
Latest posts
Firalis Molecular Precision joins Janvier Group Biosciences 10.02.26 Huningue, France, February 10, 2026 – Firalis Molecular Precision, a company specialized in biomarkers and multi-omic analyses for...
International Day of Women and Girls in Science at FMP 11.02.26 Celebrating Women in STEM Huningue, France – International Day of Women and Girls in Science aims to recognize the essential role of...
The European Union is supporting the industrial development of Firalis Molecular Precision's new site in Huningue with funding for the EXOPROD project. 23.07.25 Huningue, France – Firalis...
Share this article on your socials